{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:36:08Z","timestamp":1789043768425,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104706","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:20:06Z","timestamp":1768868406000},"page":"104706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"Hannah","family":"Bacon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang Y.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui Amy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Tadic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Anne","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.breast.2026.104706_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104706_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104706_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.breast.2026.104706_bib4","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104706_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-Endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104706_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.05.024","article-title":"Toxicity and timing of breast radiation therapy with overlapping systemic therapies","volume":"114","author":"Alcorn","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.breast.2026.104706_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijrobp.2021.12.173","article-title":"Local therapy outcomes and toxicity from the ATEMPT trial (TBCRC 033): a phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-Positive breast cancer","volume":"113","author":"Bellon","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.breast.2026.104706_bib8","article-title":"Post hoc analysis of adjuvant RT in the phase 3 KEYNOTE-522 study: neoadjuvant pembro + chemo vs. placebo + chemo followed by adjuvant pembro vs. placebo for early TNBC","author":"McArthur","year":"2022","journal-title":"San Antonio Breast Cancer Symp."},{"key":"10.1016\/j.breast.2026.104706_bib9","article-title":"Real-world safety of concurrent pembrolizumab and radiotherapy in triple-negative breast cancer","author":"El Fakih","year":"2025","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104706_bib10","article-title":"Tolerance of concurrent adjuvant radiation therapy and pembrolizumab for triple negative breast cancer: real life experience","volume":"9","author":"Tison","year":"2024","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104706_bib11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ijrobp.2024.01.001","article-title":"Immunotherapy and radiation therapy sequencing in breast cancer: a systematic review","volume":"118","author":"Verma","year":"2024","journal-title":"Int. J. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.breast.2026.104706_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10549-020-05708-0","article-title":"Utilization patterns and temporal trends of internal mammary nodal irradiation at a tertiary cancer center","volume":"182","author":"Misra","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104706_bib13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ijrobp.2010.09.026","article-title":"Rapid automated treatment planning process to select breast cancer patients for active breathing control to achieve cardiac dose reduction","volume":"82","author":"Wang","year":"2012","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.breast.2026.104706_bib14","series-title":"Common terminology criteria for adverse events (CTCAE)","year":"2017"},{"key":"10.1016\/j.breast.2026.104706_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109805","article-title":"Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis","volume":"186","author":"Salvestrini","year":"2023","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104706_bib16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","article-title":"Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)Adjuvant therapy for human epidermal growth factor receptor 2\u2013Positive early-stage breast cancer","volume":"33","author":"Krop","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104706_bib17","article-title":"Trastuzumab deruxtecan in residual HER2-Positive early breast cancer","author":"Loibl","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104706_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"3 Suppl","key":"10.1016\/j.breast.2026.104706_bib19","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.breast.2026.104706_bib20","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0360-3016(01)01685-6","article-title":"Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer","volume":"51","author":"Hernando","year":"2001","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.breast.2026.104706_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111144","article-title":"Association of artificial intelligence-screened interstitial lung disease with radiation pneumonitis in locally advanced non-small cell lung cancer","author":"Bacon","year":"2025","journal-title":"Radiother Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:30:04Z","timestamp":1775683804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"alternative-id":["S0960977626000160"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104706","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104706"}}